OCE’s Project 5 in 5 seeks to inspire pragmatic innovation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like? 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA
Table of Contents

YOU MAY BE INTERESTED IN

FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”
Steven C. Cunningham, MD, MLA, FACS
Clinical reviewer, Gastrointestinal Cancers Team, Division of Oncology 3, CDER, FDA
Donna R. Rivera, PharmD, MS
Associate director, Pharmacoepidemiology and Oncology RWE, Oncology Center of Excellence, FDA
Richard Pazdur, MD
Director, Oncology Center of Excellence, FDA
Kelly J. Norsworthy, MD
Associate director, Research Mentorship, Oncology Center of Excellence, FDA
Jennifer Gao, MD
Associate director, Education, Oncology Center of Excellence, FDA

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login